New drug combo aims to extend life in tough lung cancer

NCT ID NCT05874401

Recruiting now Disease control Sponsor: Pharmacosmos A/S Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether adding trilaciclib before standard chemotherapy (topotecan) can help people with extensive-stage small cell lung cancer live longer. About 302 participants will receive either trilaciclib or a placebo before their chemo, and researchers will compare overall survival. The trial is double-blind, meaning neither patients nor doctors know who gets the real drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trilaciclib (a drug given before chemotherapy to protect healthy cells)
What this could lead to: If it works, this could show that trilaciclib helps people with advanced small cell lung cancer live longer or have better outcomes when combined with standard chemotherapy.
What could go wrong: This is a Phase 4 trial, but it's testing non-inferiority (whether trilaciclib is at least as good as placebo). The drug may not improve survival, and side effects from chemotherapy remain a risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Hospital
RECRUITING

Seville, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.